July 07, 2026

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

Conexiant

July 07, 2026

More Physicians Enter Politics

Viewpoint explores how more physician-candidates could reshape both public service and public trust in medicine.

Conexiant

July 06, 2026

FDA Issues CRL for Orviglance NDA

Ascelia Pharma plans to request a Type A meeting with the FDA following receipt of a Complete Response Letter.

Conexiant

June 30, 2026

FDA Issues CRL for Oxylanthanum Carbonate

The action relates to previously identified third-party manufacturing deficiencies rather than concerns about the clinical efficacy or safety data, according to the company.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

June 26, 2026

Identity Formation May Shape Residency Emotions

A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.

Conexiant

June 18, 2026

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Conexiant

June 18, 2026

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Conexiant

June 17, 2026

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

Conexiant

June 12, 2026

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

Conexiant